MAPT and Alzheimer disease: The authors show that higher concentrations of disease-associated microglial activation stage 2 (DAM2) markers are associated with reduced tau accumulation and slower cognitive decline in nondemented individuals at risk for developing Alzheimer’s disease, suggesting that microglial activation delays disease progression.